

# Bleeding and Thrombosis

**Better answers** from  
high-quality testing



.....  
[Bleeding profiles and screening tests ▶](#)  
.....

[von Willebrand disease ▶](#)  
.....

[Factor assays and inhibitors ▶](#)  
.....

[Anticoagulant/Antiplatelet therapy ▶](#)  
.....

[HIT, TTP, and platelet studies ▶](#)  
.....

[Fibrinolysis and markers of thrombin generation ▶](#)  
.....

[Thrombotic risk markers and profiles – inherited ▶](#)  
.....

[Antiphospholipid antibody & lupus anticoagulant ▶](#)  
.....

[Women's health ▶](#)  
.....

[Enhanced reporting ▶](#)  
.....

## Bleeding and thrombosis **test menu**

Quest Diagnostics offers a comprehensive menu of routine and esoteric tests for bleeding and thrombosis. We have organized our test menu by category for easy navigation. Simply click on a category to the left to view the tests available for ordering. You can also scroll down to view the entire menu, as well as valuable tools like specimen collection instructions/video, a list of tests affected by anticoagulants, pediatric reference ranges, and more.

Our physicians and scientists provide diagnostic insights in the form of interpretive messages, consultative reports, test FAQs, and physician consults. We also recognize the importance of timely results and are a leader in time-to-result testing with high clinical imperatives (eg, ADAMTS13 Activity, Heparin-dependent platelet antibody testing).

Our Medical Team is available to assist with any inquiries at 1.866.MY.QUEST (1.866.697.8378) or by contacting our locations directly.

### **Quest Diagnostics:**

Chantilly, VA 1.800.336.3718

San Juan Capistrano, CA 1.800.642.4657

## Bleeding profiles and screening tests

| Test name   | Test codes          | Panel components   | Specimen requirements  |
|---|---------------------|--|--|
| Alpha-2-Antiplasmin                                 | 4953                |  | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.6 mL minimum   |
| Fibrinogen Activity, Clauss                         | 461                 |  | 1 room-temperature, full, unopened 3.2% sodium citrate (light blue-top) tube or 0.5 mL frozen platelet-poor plasma minimum |
| Mixing Study  | 8922                | Always includes PT, PTT-LA and interpretation. Possible reflexes are PT 1:1 Immediate Mixing Study and/or PTT-LA 1:1 Immediate and Incubated Mixing Study  | 2.0 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 1.5 mL minimum                             |
| Partial Thromboplastin Time, Activated III          | 763                 |  | 1 room-temperature, full, unopened 3.2% sodium citrate (light blue-top) tube or 0.5 mL frozen platelet-poor plasma minimum |
| Prothrombin Time with INR                           | 8847                |  | 1 room-temperature, full, unopened 3.2% sodium citrate (light blue-top) tube or 0.5 mL frozen platelet-poor plasma minimum |
| Reptilase Clotting Time                             | 37700               |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Thrombin Clotting Time                              | 883                 |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Prolonged aPTT Bleeding Evaluation <sup>1</sup>     | 19644X <sup>a</sup> | Always includes aPTT, interpretation. Possible reflexes: aPTT Mixing Study, FVIII, FIX, FXI Activities, VWF Antigen, Ristocetin Cofactor Activity, Thrombin Time, Hexagonal Phase Confirm                      | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube])                                |
| Prolonged aPTT Asymptomatic Evaluation <sup>1</sup> | 19645X <sup>a</sup> | Always includes: aPTT, Thrombin Time, interpretation. Possible reflexes: aPTT Mixing Study, FVIII, FIX, FXI Activities, Hexagonal Phase Confirm, VWF Antigen, Ristocetin Cofactor, Heparin Anti-Xa, Fibrinogen | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.5-mL tubes minimum |
| Prolonged aPTT Thrombotic Evaluation <sup>1</sup>   | 19648 <sup>a</sup>  | Always includes: PTT-LA, DRVVT Screen, Interpretation. Possible reflexes: Hexagonal Phase Confirm, Thrombin Time, DRVVT Confirm, DRVVT Mixing Study, Fibrinogen, PT  | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.5-mL tubes minimum |
| Prolonged PT Evaluation <sup>1</sup>                | 19643X <sup>a</sup> | Always includes: PT-INR, interpretation. Possible reflexes: PT Mixing Study, FV, FVII, FX Activities   | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.5-mL tubes minimum |
| Thrombin Clotting Time with Reflex to Mixing Study  | 144598 <sup>a</sup> | Includes Thrombin Clotting Time (TT) with reflex to Mixing Study when the TT is prolonged  | Two (2) 1-mL frozen platelet-poor plasma tubes (3.2% sodium citrate [light blue-top tube]); two (2) 0.5-mL tubes minimum   |

<sup>a</sup>Chantilly only.

All panel components can be ordered separately. Reflex tests are performed at an additional charge and are associated with an additional CPT® code.

## von Willebrand disease

| Test name  | Test codes          | Panel components   | Specimen requirements  |
|--|---------------------|--|--|
| Factor VIII Activity, Clotting   | 347                 |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| Ristocetin Cofactor Activity   | 4459                |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| von Willebrand Antigen, Multimeric <sup>2</sup>                                | 5168                |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| von Willebrand Disease Panel without Collagen Binding Assay (CBA) <sup>2</sup> | 19790               | aPTT; Factor VIII Activity, Clotting; von Willebrand Factor Antigen; Ristocetin Cofactor; von Willebrand Antigen, Multimeric Analysis; Interpretation  | Four (4) 1-mL tubes frozen plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.75-mL tubes, minimum                           |
| von Willebrand Disease Panel with Collagen Binding Assay (CBA) <sup>2</sup>    | 15540               | aPTT, Factor VIII Activity Clotting; von Willebrand Factor Antigen; Ristocetin Cofactor; von Willebrand Factor Collagen Binding Assay; von Willebrand Antigen Multimeric Analysis  | Four (4) 1-mL tubes frozen plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.75-mL tubes, minimum                           |
| von Willebrand Comprehensive Panel 2 with Consultation <sup>2</sup>            | 19681X <sup>a</sup> | aPTT; Factor VIII Activity Clotting; von Willebrand Factor Antigen; Ristocetin Cofactor; von Willebrand Factor Collagen Binding Assay; von Willebrand Multimeric Analysis; Interpretation; Coagulation Consultative Report | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| von Willebrand Factor Antigen  | 4919                |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| von Willebrand Factor Collagen Binding Assay <sup>2</sup>                      | 10924               |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| von Willebrand Screen  | 90271               | aPTT; Factor VIII Activity, Clotting; von Willebrand Factor Antigen; Ristocetin Cofactor   | Three (3) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); three (3) 0.75 mL tubes minimum            |
| von Willebrand Disease Gene Sequencing   | 36494               |  | 5 mL whole blood collected in EDTA (lavender-top), ACD (yellow-top), sodium heparin (green-top), or sodium heparin (royal blue-top) tube |

## Factor assays and inhibitors

| Test name                        | Test codes | Panel components | Specimen requirements  |
|----------------------------------|------------|------------------|--|
| Fibrinogen Activity, Clauss      | 461        |                  | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum               |
| Fibrinogen Antigen, Nephelometry | 37801      |                  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum |
| Factor II Activity, Clotting     | 331        |                  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum |

<sup>a</sup>Chantilly only.

All panel components can be ordered separately. Reflex tests are performed at an additional charge and are associated with an additional CPT® code.

## Factor assays and inhibitors (continued)

| Test name   | Test codes | Panel components  | Specimen requirements  |
|---|------------|---|--|
| Factor V Activity and Human Inhibitor                         | 17844      | If FV Activity $\leq$ 20%, then FV Inhibitor (Bethesda Assay) will be performed   | Two (2) 2-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL tubes minimum |
| Factor V Activity, Clotting                                   | 344        |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor VII Activity, Clotting                                 | 346        |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor VIII Antigen   | 90879      |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor VIII Activity, Chromogenic                             | 16049      |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor VIII Activity, Clotting                                | 347        |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor VIII Inhibitor Panel                                   | 40083      | Includes FVIII Activity, Clotting and FVIII Inhibitor, EIA Screen. If EIA positive, then FVIII Human Inhibitor (Nijmegen Assay) performed | Two (2) 2-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL tubes minimum |
| Factor IX Activity and Human Inhibitor                        | 17845      | If FIX Activity $\leq$ 20%, then FIX Inhibitor (Bethesda Assay) performed   | Two (2) 2-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL tubes minimum |
| Factor IX Activity, Clotting                                  | 352        |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor IX Antigen   | 91053      |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor X Activity, Chromogenic                                | 10663      |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor X Activity, Clotting                                   | 359        |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor XI Activity, Clotting                                  | 360        |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor XI Activity and Human Inhibitor                        | 17854      | If FXI Activity $\leq$ 20%, then FXI Inhibitor (Bethesda Assay) performed   | Two (2) 2-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL tubes minimum |
| Factor XI Mutation Analysis (Ashkenazi Jewish) <sup>2,3</sup> | 16023      |   | 5 mL room-temperature whole blood (EDTA [lavender-top tube]); 3 mL minimum   |
| Factor XII Activity, Clotting                                 | 362        |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                           |
| Factor XIII, Functional <sup>2</sup>                          | 14461      |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.3 mL minimum                           |

## Anticoagulant/Antiplatelet therapy

| Test name  | Test codes          | Panel components   | Specimen requirements  |
|--|---------------------|--|--|
| AccuType® Warfarin <sup>3,4</sup>                              | 16160               | Includes variations in 2 genes ( <i>VKORC1</i> and <i>CYP2C9</i> ) | 5 mL room-temperature whole blood (EDTA [lavender-top tube]); 3 mL minimum   |
| Apixaban   | 94223               |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                             |
| AccuType® CP, Clopidogrel <i>CYP2C19</i> Genotype <sup>a</sup> | 16924<br>(16925 NY) |  | 4 mL whole blood (EDTA [lavender-top tube]); 2 mL whole blood minimum • 1 mL saliva minimum                              |
| Cardio IQ® <i>CYP2C19</i> Genotype <sup>a</sup>                | 90668               |  | 4 mL whole blood (EDTA [lavender-top tube]); 2 mL minimum  |
| Fondaparinux Sodium (Xa Inhibition; Arixtra™)                  | 16103               |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                             |
| Heparin, Anti-Xa for UFH and LMWH                              | 30292               |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                             |
| Prothrombin Time with INR                                      | 8847                |  | 1 room-temperature, full, unopened 3.2% sodium citrate (light blue-top) tube; 0.5 mL frozen platelet-poor plasma minimum |
| Rivaroxaban  | 90981               |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                             |
| Vitamin K  | 36585               |  | 4 mL frozen plasma (sodium heparin [green-top tube]); 2 mL minimum   |

## HIT, TTP, and platelet studies

| Test name  | Test codes | Panel components   | Specimen requirements   |
|--|------------|--|---|
| ADAMTS13 Activity with Reflex to Inhibitor <sup>2</sup>                      | 14532      | ADAMTS13 activity with reflex to ADAMTS13 inhibitor when activity is ≤30%                                  | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum        |
| AspirinWorks® 11-Dehydrothromboxane B2 (11-dhTXB2) with Creatinine           | 16174      |  | 4 mL room-temperature random urine (BD C&S Vacutainer® tube); 3 mL minimum            |
| Heparin-Induced Platelet Antibody  | 414        |  | 1 mL frozen serum (red-top [no gel] tube); 0.5 mL minimum                             |
| Heparin-Induced Platelet Antibody with Reflex to SRA, Unfractionated Heparin | 15334      | Reflex to SRA (unfractionated heparin) when heparin-induced antibody weak positive or positive             | Two (2) 1-mL tubes frozen serum, two 0.5-mL tubes minimum                             |
| Heparin-Induced Thrombocytopenia Panel <sup>3</sup>                          | 14874      | Serotonin Release Assay (SRA), Unfractionated Heparin; Heparin-Induced Platelet Antibody                   | Two (2) 1-mL tubes frozen serum (red-top [no gel] tube), two (2) 0.9-mL tubes minimum |
| Human Platelet Antigen 1 Genotype  | 10707      | Detects variant that may lead to neonatal alloimmune thrombocytopenia                                      | 5 mL room-temperature whole blood (EDTA [lavender-top tube]); 1 mL minimum            |
| Platelet Antibody Screen, Serum  | 11484      | GPIIb/IIIa (Cell-1); GPIIb/IIIa (Cell-2); GPIa/IIa (Cell-1); GPIa/IIa (Cell-2); GPIb/IX; GPIV; HLA Class I | 1.5 mL frozen serum (red-top [no gel] tube); 0.5 mL minimum                           |

<sup>a</sup>Chantilly only.

All panel components can be ordered separately. Reflex tests are performed at an additional charge and are associated with an additional CPT® code.

## HIT, TTP, and platelet studies (continued)

| Test name  | Test codes | Panel components  | Specimen requirements  |
|--|------------|---|--|
| Platelet Antibody, Direct, Flow Cytometry <sup>5</sup> | 5019       | Detects platelet-associated IgG, IgA and IgM antibodies | 7 mL room-temperature whole blood (EDTA [lavender-top tube]); 5 mL minimum |
| Serotonin Release Assay (SRA), LMWH <sup>3</sup>       | 16284      |   | 1 mL frozen serum; 0.4 mL minimum  |
| Serotonin Release Assay (SRA), Unfractionated Heparin  | 14627      |   | 1 mL frozen serum; 0.4 mL minimum  |

## Fibrinolysis and markers of thrombin generation

| Test name  | Test codes         | Panel components   | Specimen requirements  |
|--|--------------------|--|--|
| D-Dimer, Quantitative  | 8659               |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Euglobulin Clot Lysis Time                                     | 462                |  | 2 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 1 mL minimum   |
| Fibrin Monomer   | 11074              |  | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| Fibrinogen Activity, Clauss                                    | 461                |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Fibrinogen Antigen, Nephelometry                               | 37801              |  | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| Fibrinogen Degradation Products (FDP)                          | 458                |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Fibrinogen Comprehensive Panel with Consultation               | 19903 <sup>a</sup> | Fibrinogen Activity, Clauss; Thrombin Clotting Time with Reflex to Mixing Study; Reptilase Clotting Time; Fibrinogen Antigen, Nephelometry; Coagulation Consult  | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light-blue top tube]); four (4) 0.5-mL tubes minimum |
| Fibrinogen Comprehensive Panel without Consultation            | 14458              | Fibrinogen Activity, Clauss; Thrombin Clotting Time with Reflex to Mixing Study; Reptilase Clotting Time; Fibrinogen Antigen, Nephelometry   | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light-blue top tube]); four (4) 0.5-mL tubes minimum |
| Fibrinolysis Comprehensive Panel                               | 90923              | Alpha 2-Antiplasmin; D-Dimer, Quantitative; Euglobulin Clot Lysis Time; Fibrinogen Degradation Products, Semi-Quantitative; Plasminogen Activator Inhibitor-1; Plasminogen Activity; Tissue Plasminogen Activator, EIA; Fibrin Monomer | Five (5) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); five (5) 0.8-mL tubes minimum |
| Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G <sup>3,4</sup> | 11368              |  | 5 mL room-temperature whole blood (EDTA [lavender-top tube]); 3 mL minimum   |
| Plasminogen Activity   | 4458               |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |

<sup>a</sup>Chantilly only.

All panel components can be ordered separately. Reflex tests are performed at an additional charge and are associated with an additional CPT® code.

## Fibrinolysis and markers of thrombin generation (continued)

| Test name                                 | Test codes | Panel components  | Specimen requirements  |
|---|------------|---|--|
| Plasminogen, Antigenic                    | 5164       |   | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| Prothrombin Fragment 1.2                  | 37674      |   | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| Thrombin-Antithrombin (TAT) Complex       | 10162      |   | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum   |
| Tissue Plasminogen Activator (TPA), EIA   | 29816      |   | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.3 mL minimum   |
| Thrombotic Marker Panel with Consultation | 19685      | D-Dimer, Fibrin Monomer, Prothrombin Fragment 1.2, Thrombin-Antithrombin (TAT) Complex; Coagulation Consult | Three (3) 2-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light-blue top tube]); three (3) 1-mL tubes minimum |
| Thrombotic Marker Panel                   | 11345X     | D-Dimer, Fibrin Monomer, Prothrombin Fragment 1.2, Thrombin-Antithrombin (TAT) Complex                      | Three (3) 2-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light-blue top tube]); three (3) 1-mL tubes minimum |

## Thrombotic risk markers and profiles—**inherited/acquired**

| Test name   | Test codes | Panel components   | Specimen requirements   |
|---|------------|--|---|
| Activated Protein C-Resistance  | 22         |  | 2 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 1 mL minimum  |
| Activated Protein C Resistance with Reflex to Factor V (Leiden) Mutation <sup>5</sup> | 19704      | If APCR <2.1 ratio, Factor V Leiden Mutation will be performed | 2 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]) and 4 mL frozen whole blood (EDTA [lavender-top tube]); 1 mL plasma and 2 mL whole blood minimum |
| Antithrombin III Activity   | 216        |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum  |
| Antithrombin III Activity and Antigen   | 7017       |  | Two (2) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 0.5-mL tubes minimum  |
| Antithrombin III Activity with Reflex to Antithrombin III Antigen                     | 8267       | If ATIII Activity decreased, ATIII Antigen will be performed   | Two (2) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 0.5-mL tubes minimum  |
| Antithrombin III Antigen  | 5158       |  | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum  |
| Factor V (Leiden) Mutation Analysis <sup>5</sup>                                      | 17900      |  | 5 mL room-temperature whole blood (EDTA [lavender-top tube]); 3 mL minimum  |
| Homocysteine  | 31789      |  | 1 mL room-temperature serum (red-top [no gel] tube); 0.5 mL minimum   |
| Lipoprotein (a)   | 34604      |  | 1 mL room-temperature serum (red-top [no gel] tube); 0.5 mL minimum   |



## Thrombotic risk markers and profiles—*inherited/acquired* (continued)

| Test name   | Test codes         | Panel components  | Specimen requirements  |
|---|--------------------|---|--|
| Methylenetetrahydrofolate Reductase (MTHFR), DNA Mutation Analysis <sup>5</sup> | 17911              |   | 5 mL room-temperature whole blood (EDTA [lavender-top tube]); 3 mL minimum   |
| Prolonged aPTT Thrombotic Evaluation <sup>6</sup>                               | 19648 <sup>a</sup> | Always includes: PTT-LA, DRVVT Screen, Interpretation. Possible reflexes: Hexagonal Phase Confirm, Thrombin Time, DRVVT Confirm, DRVVT Mixing Study, Fibrinogen, PT | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.5-mL tubes minimum |
| Protein C Activity  | 1777               |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Protein C Activity and Antigen  | 8757               |   | Two (2) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 0.5-mL tubes minimum   |
| Protein C Activity with Reflex to Protein C Antigen                             | 8754               | If Protein C Activity is decreased, Protein C Antigen will be performed   | Two (2) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 0.5-mL tubes minimum   |
| Protein C and Protein S, Functional   | 39457              | Protein C Activity, Protein S Activity  | Two (2) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 0.5-mL tubes minimum   |
| Protein C and S Activity with Reflex to Protein C and/or S Antigen              | 7942               | If Protein C Activity is decreased, Protein C Antigen is performed. If Protein S Activity is decreased, Protein S Antigen, Total is performed                       | Two (2) 2-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL tubes minimum     |
| Protein C Antigen   | 4948               |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Protein S Activity  | 1779               |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Protein S Activity with Reflex to Protein S Antigen, Total and Free             | 17494              | If Protein S Activity is decreased, Protein S Antigen Total and Free will be performed  | 2 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 1 mL minimum                                 |
| Protein S Antigen, Free   | 10170              |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Protein S Antigen, Total  | 5165               |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Protein S Antigen, Total and Free   | 36457              |   | 2 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 1 mL minimum                                 |
| Prothrombin Factor II 20210G>A Mutation Analysis <sup>5</sup>                   | 17909              |   | 5 mL room-temperature whole blood (EDTA [lavender-top tube]); 3 mL minimum   |
| Thrombophilia DNA Mutation Analysis <sup>5</sup>                                | 17907              | Factor V (Leiden) and Prothrombin (Factor II) Gene Analysis   | 5 mL room-temperature whole blood (EDTA [lavender-top tube]); 3 mL minimum   |

<sup>a</sup>Chantilly only.

All panel components can be ordered separately. Reflex tests are performed at an additional charge and are associated with an additional CPT® code.

## Thrombotic risk markers and profiles—**inherited/acquired** (continued)

| Test name  | Test codes | Panel components  | Specimen requirements  |
|--|------------|---|--|
| Thrombophilia Screen II, Inherited <sup>5</sup>                        | 11327      | Factor V (Leiden) Mutation with Reflex to HR2 Mutation Analysis; Prothrombin Gene Mutation; Antithrombin III Activity; Protein C Activity; Protein S Antigen, Free  | Three (3) 1-mL tubes frozen plasma (3.2% sodium citrate [light blue-top tube]) and 5 mL whole blood (EDTA [lavender-top tube]); three (3) 0.5-mL tubes plasma and 5 mL whole blood minimum                                 |
| Venous Thrombosis Hypercoagulability Panel w/Reflex (Warfarin Patient) | 11472      | Activated Protein C Resistance with Reflex to Factor V (Leiden) Mutation; Prothrombin (Factor II) 20210G→A Mutation Analysis; Antithrombin III Activity; Factor VIII Activity, Clotting; Hexagonal Phase Confirm; dRVVT Screen with Reflex to dRVVT Confirm and dRVVT 1:1 Mix; Cardiolipin Antibodies (IgG, IgM); Beta-2-Glycoprotein I Antibodies (IgG, IgM)<br><br>If Activated Protein C-Resistance is positive, then Factor V (Leiden) Mutation Analysis will be performed. If dRVVT Screen is prolonged, then dRVVT Confirm will be performed. If dRVVT Confirm is positive, then dRVVT 1:1 Mixing Study will be performed   | 5 mL whole blood (EDTA [lavender-top tube]) and six (6) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tubes]); six (6) 0.5-mL frozen platelet-poor plasma and 3 mL whole blood minimum       |
| Venous Thrombosis Hypercoagulability Panel w/Reflex                    | 11475      | Activated Protein C Resistance with Reflex to Factor V (Leiden) Mutation; Prothrombin (Factor II) 20210G→A Mutation Analysis; Protein C Activity; Protein S Antigen, Total and Free; Antithrombin III Activity; Factor VIII Activity, Clotting; Lupus Anticoagulant Evaluation with Reflex (PTT-LA and dRVVT with Reflex Confirmations); Cardiolipin Antibodies (IgG, IgM); Beta-2-Glycoprotein I Antibodies (IgG, IgM)<br><br>If Activated Protein C-Resistance is positive, then Factor V (Leiden) Mutation Analysis will be performed<br><br>If PTT-LA Screen is prolonged, then Hexagonal Phase Confirmation will be performed. If Hexagonal Phase Confirmation is positive or weakly positive, then Thrombin Clotting Time will be performed. If dRVVT Screen is prolonged then dRVVT Confirm will be performed. If dRVVT Confirm is positive, then dRVVT 1:1 Mixing Study will be performed | 5 mL whole blood (EDTA [lavender-top tube]) and six (6) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tubes]); six (6) 0.5-mL tubes frozen platelet-poor plasma and 3 mL whole blood minimum |

## Thrombotic risk markers and profiles—**inherited/acquired** (continued)

| Test name   | Test codes | Panel components  | Specimen requirements   |
|---|------------|---|---|
| Venous Thrombosis Hypercoag Panel w/Reflex, Consultation (Warfarin Patient) | 19655      | <p>Activated Protein C Resistance with Reflex to Factor V (Leiden) Mutation; Prothrombin (Factor II) 20210G→A Mutation Analysis; Antithrombin III Activity; Homocysteine; Cardiolipin Antibodies (IgG, IgM); Factor VIII Activity, Clotting; Beta-2-Glycoprotein I Antibodies (IgG, IgM); Hexagonal Phase Confirmation; dRVVT Screen with Reflex to dRVVT Confirm and dRVVT 1:1 Mix; Coagulation Consultation</p> <p>If Activated Protein C-Resistance is positive, then Factor V (Leiden) Mutation Analysis will be performed. If dRVVT Screen is prolonged, then dRVVT Confirm will be performed. If dRVVT Confirm is positive, then dRVVT 1:1 Mixing Study will be performed</p>   | 5 mL whole blood ([EDTA (lavender-top tube)] and six (6) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tubes]) and 1 mL serum; six (6) 0.5-mL tubes minimum frozen platelet-poor plasma, 0.6 mL serum, and 3 mL whole blood minimum |
| Venous Thrombosis Hypercoagulability Panel w/Reflex and Consultation        | 19656      | <p>Activated Protein C Resistance with Reflex to Factor V (Leiden) Mutation; Prothrombin (Factor II) 20210G→A Mutation Analysis; Protein C Activity; Protein S Antigen, Free and Protein S Antigen, Total; Antithrombin III Activity; Homocysteine; Cardiolipin Antibodies (IgG, IgM); Factor VIII Activity, Clotting; Beta-2-Glycoprotein I Antibodies (IgG, IgM); Lupus Anticoagulant Evaluation with Reflex (PTT-LA and dRVVT with Reflex Confirmations); Coagulation Consultation</p> <p>If Activated Protein C-Resistance is positive, then Factor V (Leiden) Mutation Analysis will be performed. If PTT-LA Screen is prolonged, then Hexagonal Phase Confirmation will be performed. If Hexagonal Phase Confirmation is positive or weakly positive, then Thrombin Clotting Time will be performed. If dRVVT Screen is prolonged then dRVVT Confirm will be performed. If dRVVT Confirm is positive, then dRVVT 1:1 Mixing Study will be performed</p> | 5 mL whole blood (EDTA [lavender-top tube]) and six (6) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tubes] and 1 mL serum; six (6) 0.5-mL tubes minimum frozen platelet-poor plasma, 0.5 mL serum and 3 mL whole blood minimum    |

## Antiphospholipid antibody and lupus anticoagulant

| Test name                                  | Test codes | Panel components   | Specimen requirements   |
|--|------------|--|---|
| Antiphospholipid Antibody Panel            | 14890      | Beta-2-Glycoprotein I Antibodies (IgG, IgA, IgM); Phosphatidylserine/Prothrombin (PS/PT) Antibodies (IgG, IgM); Cardiolipin Antibodies (IgA, IgG, IgM) | Two (2) 1-mL tubes of plasma (3.2% sodium citrate, [light blue-top tubes]); Two (2) 0.5-mL minimum          |
| Antiphospholipid Syndrome Diagnostic Panel | 19872      | Cardiolipin and Beta-2-Glycoprotein I Antibodies (IgG, IgA, IgM); Lupus Anticoagulant Evaluation with Reflex   | Three (3) 1-mL tubes platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL minimum |

## Antiphospholipid antibody and lupus anticoagulant (continued)

| Test name  | Test codes         | Panel components  | Specimen requirements  |
|--|--------------------|---|--|
| Beta-2-Glycoprotein I Antibodies (IgA, IgG, IgM)                                       | 30340              | Beta-2-Glycoprotein I Antibodies (IgA) TC 36552; Beta-2-Glycoprotein I Antibodies (IgG) TC 36554; Beta-2-Glycoprotein I Antibodies (IgM) TC 36553   | 3 mL room-temperature plasma (3.2% sodium citrate [light blue-top tube]); 1.5 mL minimum                                   |
| Beta-2-Glycoprotein I Antibodies (IgG, IgM)  | 91244              | Beta-2-Glycoprotein I Antibodies (IgG) TC 36554; Beta-2-Glycoprotein I Antibodies (IgM) TC 36553  | 2 mL room-temperature plasma (3.2% sodium citrate [light blue-top]); 1 mL minimum  |
| Cardiolipin Antibodies (IgA, IgG, IgM)   | 7352               | Cardiolipin Antibody (IgA) TC 4661; Cardiolipin Antibody (IgG) TC 4662; Cardiolipin Antibody (IgM) TC 4663  | 1 mL room-temperature plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                                   |
| Cardiolipin Antibodies (IgG, IgM)  | 36333              | Cardiolipin Antibody (IgG) TC 4662; Cardiolipin Antibody (IgM) TC 4663  | 1 mL room-temperature plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                                   |
| DRVVT Screen with Reflex to DRVVT Confirm and DRVVT 1:1 Mix                            | 15780              |   | 1 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum                               |
| Lupus Anticoagulant Evaluation with Reflex   | 7079               | Always includes PTT-LA; DRVVT Screen and Interpretation. Possible reflexes are Hexagonal Phase Confirm; Thrombin Clotting Time; DRVVT Confirm and DRVVT Mixing Study  | Two (2) 1.5-mL frozen tubes (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL tubes minimum                        |
| Lupus Anticoagulant and Antiphospholipid Confirmatory Panel, non-Coumadin              | 19652              | Cardiolipin and B2GPI Antibodies (IgG, IgM); Prolonged aPTT Thrombotic Evaluation   | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.5-mL tubes minimum |
| Lupus Anticoagulant and Antiphospholipid Confirmatory Panel non-Coumadin, with consult | 19654 <sup>a</sup> | Prolonged aPTT Thrombotic Evaluation; PTT-LA with Reflex to Hexagonal Phase Confirmation; dRVVT Screen with Reflex to dRVVT Confirm and dRVVT 1:1 Mix; Cardiolipin Antibodies (IgG, IgM); Beta-2-Glycoprotein I Antibodies (IgG, IgM); Coagulation Consultation | Six (6) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); six (6) 0.5-mL tubes minimum   |
| Lupus Anticoagulant and Antiphospholipid Confirmatory Panel on Coumadin                | 19672              | Cardiolipin and B2GPI Antibodies (IgG, IgM); Hexagonal Phase Confirm; dRVVT Screen with Reflex to dRVVT Confirm and dRVVT 1:1 Mix; PT with INR, Thrombin Clotting Time  | Six (6) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); six (6) 0.5-mL tubes minimum   |
| Lupus Anticoagulant and Antiphospholipid Confirmatory Panel on Coumadin, with consult  | 19674 <sup>a</sup> | Prothrombin Time with INR; Thrombin Clotting Time; Cardiolipin Antibodies (IgG, IgM); Beta-2-Glycoprotein I Antibodies (IgG, IgM); Hexagonal Phase Confirmation; dRVVT Screen with Reflex to dRVVT Confirm and dRVVT 1:1 Mix; Coagulation Consultation          | Six (6) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tubes]); six (6) 0.5-mL tubes minimum  |
| Phosphatidylserine/Prothrombin (PS/PT) Antibodies (IgG, IgM)                           | 11447              | Phosphatidylserine/Prothrombin (PS/PT) IgG 1143; Phosphatidylserine/Prothrombin (PS/PT) IgM 1146  | 1 mL platelet-poor plasma (3.2% sodium citrate [light blue-top tube])  |

<sup>a</sup>Chantilly only.

All panel components can be ordered separately. Reflex tests are performed at an additional charge and are associated with an additional CPT® code.

## Antiphospholipid antibody and lupus anticoagulant (continued)

| Test name  | Test codes | Panel components | Specimen requirements  |
|--|------------|------------------|--|
| Prothrombin Antibody (IgG)                         | 94041      |                  | 1 mL frozen plasma (3.2% sodium citrate [light blue-top tube]); 0.3 mL minimum                 |
| PTT-LA with Reflex to Hexagonal Phase Confirmation | 17408      |                  | 1.5 mL frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); 0.5 mL minimum |

## Women's health

| Test name   | Test codes         | Panel components  | Specimen requirements  |
|---|--------------------|---|--|
| Menorrhagia Screen without Consultation                                     | 19649              | aPTT; PT with INR; Factor XI Activity; von Willebrand Factor Antigen; Ristocetin Cofactor Activity; Factor VIII Activity  | Three (3) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL tubes minimum   |
| Menorrhagia Screen with Consultation  | 19651 <sup>a</sup> | aPTT; PT with INR; Factor XI Activity; von Willebrand Factor Antigen; Ristocetin Cofactor Activity; Factor VIII Activity; Coagulation Consultative Report   | Three (3) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); two (2) 1-mL tubes minimum   |
| Recurrent Miscarriage/Coagulation Panel with Reflex (without Consultation)  | 11469              | Lupus Anticoagulant Evaluation with Reflex (PTT-LA and dRVVT with Reflex Confirmations); Cardiolipin and Beta-2-Glycoprotein I Antibodies (IgG, IgA, IgM); Protein C Activity; Protein S Antigen, Free; Antithrombin III Activity; Phosphatidylserine/Prothrombin Antibodies (IgG, IgM); Prothrombin (Factor II) 20210G→A Mutation Analysis; Factor V (Leiden) Mutation Analysis                        | 5 mL whole blood collected in an EDTA (lavender-top) tube and Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube])<br><br>Minimum: 3 mL EDTA whole blood; four (4) 0.5-mL tubes platelet-poor plasma (sodium citrate)   |
| Recurrent Miscarriage Evaluation/Coagulation Panel with Consultation        | 19671 <sup>a</sup> | Lupus Anticoagulant Evaluation with Reflex (PTT-LA and dRVVT with Reflexes); Cardiolipin and Beta-2-Glycoprotein I Antibodies (IgG, IgA, IgM); Protein C Activity; Protein S Antigen, Free; Antithrombin III Activity; Phosphatidylserine/Prothrombin Antibodies (IgG, IgM); Prothrombin (Factor II) 20210G > A Mutation Analysis; Factor V (Leiden) Mutation Analysis; Coagulation Consultative Report | 5 mL whole blood collected in an EDTA (lavender-top) tube and Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); and 3 mL frozen serum collected in a red-top tube (no gel)<br><br>Minimum: 3 mL EDTA whole blood, four (4) 0.5-mL tubes platelet-poor plasma (sodium citrate), and 0.5 mL serum |
| von Willebrand Disease Panel without Collagen Binding Assay (CBA)           | 19790              | aPTT; Factor VIII Activity, Clotting; von Willebrand Factor Antigen; Ristocetin Cofactor Activity; von Willebrand Factor Multimeric Analysis; Interpretation  | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.75-mL tubes minimum  |
| von Willebrand Disease Panel with Collagen Binding Assay (CBA) <sup>2</sup> | 15540              | aPTT; Factor VIII Activity Clotting; von Willebrand Factor Antigen; Ristocetin Cofactor Activity; von Willebrand Factor Collagen Binding Assay; von Willebrand Factor Multimeric Analysis; Interpretation   | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.75-mL tubes minimum  |

<sup>a</sup>Chantilly only.

All panel components can be ordered separately. Reflex tests are performed at an additional charge and are associated with an additional CPT® code.

| Test name   | Test codes          | Panel components   | Specimen requirements  |
|---|---------------------|--|--|
| von Willebrand Comprehensive Panel 2 with Consultation <sup>2</sup> | 19681X <sup>a</sup> | aPTT; Factor VIII Activity Clotting; von Willebrand Factor Antigen; Ristocetin Cofactor Activity; von Willebrand Factor Collagen Binding ASSAY; von Willebrand Factor Multimeric Analysis; Interpretation; Coagulation Consultative Report | Four (4) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); four (4) 0.75-mL tubes minimum  |
| von Willebrand Screen   | 90271               | aPTT; Factor VIII Activity, Clotting; von Willebrand Factor Antigen; Ristocetin Cofactor   | Three (3) 1-mL tubes frozen platelet-poor plasma (3.2% sodium citrate [light blue-top tube]); three (3) 0.5-mL tubes minimum |

## Enhanced reporting

| Test name                | Test codes | Panel components  | Specimen requirements |
|--------------------------|------------|---|-----------------------|
| Coagulation Consultation | 19682      | A consultative report can be added to any single or group of test codes performed at the Chantilly Laboratory |                       |

<sup>1</sup>The Prolonged aPTT and PT panels are only available at the Quest Diagnostics Chantilly, VA laboratory.

<sup>2</sup>This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics. This test should not be used for diagnosis without confirmation by other medically established means.

<sup>3</sup>This test was developed and its performance characteristics have been determined by Quest Diagnostics. Performance characteristics refer to the analytical performance of the test.

<sup>4</sup>This test is performed pursuant to a license agreement with Orchid Biosciences Inc.

<sup>5</sup>This test was developed and its performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

<sup>6</sup>Tests only available in Chantilly, VA.

Multiple test codes may be used for a test. Please refer to your local business unit or the online Directory of Services (TestDirectory.QuestDiagnostics.com).

<sup>a</sup>Chantilly only.

All panel components can be ordered separately. Reflex tests are performed at an additional charge and are associated with an additional CPT<sup>®</sup> code.

## Tests affected by anticoagulants

It's important to note that certain anticoagulant drugs can interfere with clot-based assays, as shown in the table below.

| Test name   | Test codes         | Warfarin  | Heparin (UFH or LMWH) <sup>a</sup>   | Thrombin Inhibitors <sup>a</sup><br>(ie, Dabigatran, Argatroban)  | Factor Xa Inhibitors <sup>a</sup><br>(ie, Rivaroxaban, Apixaban, Edoxaban) |
|---|--------------------|---|--|---|--|
| aPTT  | 763                | Prolonged   | Prolonged  | Prolonged   | Prolonged  |
| PT/INR  | 8847               | Prolonged   | Little to no effect <sup>b</sup>   | Normal to prolonged   | Prolonged  |
| Fibrinogen Activity ( <i>Clauss Method</i> )  | 461                | No effect   | No effect (LMWH) to falsely low (UFH)  | No effect or falsely low  | No effect  |
| Thrombin Clotting Time  | 883                | No effect   | Prolonged  | Prolonged   | No effect  |
| aPTT-based factor assays<br>(FVIII Activity, FIX Activity, Factor XI Activity, Factor XII Activity)   | 347, 352, 360, 362 | FIX: Physiologic decrease<br><br>FVIII/XI/XII: No effect  | No effect to inhibitor pattern   | No effect to inhibitor pattern  | No effect to inhibitor pattern   |
| PT-based factor assays <sup>b</sup><br>(FII Activity, FV Activity, Factor VII Activity, Factor X Activity)  | 331, 344, 346, 359 | FII/VII/X: Physiologic decrease<br><br>Factor V: No effect  | No effect <sup>b</sup>   | No effect to inhibitor pattern or falsely low   | No effect to inhibitor pattern   |
| Antithrombin Activity ( <i>Thrombin-Based Method</i> )  | 216                | No effect   | No effect to decrease <sup>c</sup>   | May falsely increase  | No effect  |
| Antithrombin III Antigen  | 5158               | No effect   | No effect to decrease <sup>c</sup>   | No effect   | No effect  |
| Protein C Antigen   | 4948               | No effect to physiologic decrease   | No effect  | No effect   | No effect  |
| Protein C Activity<br>( <i>Clot-Based Method</i> )  | 1777               | Physiologic decrease  | UFH: No effect. LMWH: may falsely increase at higher levels  | May falsely increase  | May falsely increase   |
| Protein S Antigen, Free   | 10170              | Physiologic decrease  | No effect  | No effect   | No effect  |
| Protein S Antigen, Total  | 5165               | No effect to physiologic decrease   | No effect  | No effect   | No effect  |
| Protein S Activity<br>( <i>Clot-Based Method</i> )  | 1779               | Physiologic decrease  | May falsely increase at values ~>1.0 IU/mL   | May falsely increase  | May falsely increase   |
| Activated Protein C Resistance<br>( <i>FV-dependent Prothrombin Venom-Based Method</i> )  | 22                 | No effect   | No effect  | Unable to obtain assay end-point <sup>a</sup>   | No effect  |
| Lupus Anticoagulant Evaluation with Reflex;<br>( <i>PTT-LA with reflex to Hexagonal Phase Confirm &amp; reflex to Thrombin Time; DRVVT Screen with reflex to DRVVT Confirm and DRVVT 1:1 Mixing Study</i> ) | 7079               | Screening tests may be prolonged but confirmatory tests include mixing studies which correct for warfarin-induced factor deficiencies | Possible to misclassify as LA positive (panel may include Thrombin Time, which will detect UFH/LMWH) | Possible to misclassify as LA positive (panel may include Thrombin Time, which will detect thrombin inhibitors) | Possible to misclassify as LA positive                                     |
| Antiphospholipid Antibody Panel   | 14890              | No effect   | No effect  | No effect   | No effect  |

<sup>a</sup>Therapeutic levels. Potential interference dependent on drug concentration.

<sup>b</sup>Reagent contains a heparin neutralizer.

<sup>c</sup>UFH may decrease levels physiologically but no assay interference.

## Commonly misordered tests

Knowing when to order the correct test or differentiating between two tests with similar names can be difficult. We realize the importance of ordering the correct test the first time and have identified several tests as being “commonly misordered.” The list below provides a summary of those tests and includes the test name, test code, and appropriate use for each test. If you would like to see a full description for any test, please go to [TestDirectory.QuestDiagnostics.com](http://TestDirectory.QuestDiagnostics.com)

| Commonly misordered tests | Test codes       | Appropriate use for test code specified               | For assessment   |
|---------------------------|------------------|---|--|
| Factor II                 | 331              | Factor II Activity, Clotting                          | Bleeding risk  |
|                           | 17909            | Factor II Prothrombin 20210G>A Mutation Analysis      | Thrombotic risk  |
| Factor V                  | 344              | Factor V Activity, Clotting                           | Bleeding risk  |
|                           | 17900            | Factor V (Leiden) Mutation Analysis                   | Thrombotic risk  |
| Factor VIII               | 347              | Factor VIII Activity, Clotting                        | Bleeding/thrombotic risk   |
|                           | 16049            | Factor VIII Activity, Chromogenic                     | Bleeding/thrombotic risk in patients with lupus anticoagulants or other inhibitors   |
|                           | 40083            | Factor VIII Inhibitor Panel                           | Bleeding risk  |
|                           | 14461            | Factor XIII, Functional                               | Common clerical error, intended for bleeding risk  |
| Factor X                  | 359              | Factor X Activity, Clotting                           | Bleeding risk  |
|                           | 10663            | Factor X Activity, Chromogenic                        | Warfarin monitoring for patients with lupus anticoagulant  |
|                           | 30292            | Heparin Anti Xa                                       | Monitoring patients on heparin or LMWH; not appropriate for anti-Xa medications (direct oral anticoagulants such as apixaban, rivaroxaban, etc. see below) |
| Anti Xa (Xa Inhibition)   | 16103            | Fondaparinux Sodium (Xa Inhibition)                   | Specific anticoagulant monitoring  |
|                           | 90981            | Rivaroxaban   | Specific anticoagulant monitoring  |
|                           | 94223            | Apixaban  | Specific anticoagulant monitoring  |
|                           | 30292            | Heparin Anti-Xa                                       | Specific anticoagulant monitoring  |
| Ristocetin                | 4459             | Ristocetin Cofactor Activity                          | Bleeding risk due to von Willebrand Disease  |
|                           | Test not offered | Ristocetin-induced platelet aggregation               | Bleeding risk due to Type 2B or Platelet Type von Willebrand disease, not offered due to short specimen stability  |
| Serotonin                 | 14627            | Serotonin Release Assay (SRA), Unfractionated Heparin | Thrombotic risk  |
|                           | 818              | Serotonin, Blood                                      | Presence of carcinoid tumors of the enterochromaffin cell, common clerical error   |




## Specimen collection instructions


### Preparing platelet-poor plasma for coagulation testing

For multiple tube collection, follow the order below for blood drawing:

|            | Cap color | Collection tube         |
|------------|-----------|-------------------------|
| Draw first |           | Blood cultures          |
|            |           | Citrate tube            |
|            |           | Serum tube              |
|            |           | Heparin tube            |
|            |           | EDTA tube               |
| Draw last  |           | Fluoride (Glucose) tube |




1 Fill Vacutainer to the minimum required fill line.




2 Immediately after collection, mix specimen by gentle inversion four times.




3 Centrifuge at 1500 x g for 15 minutes.




4 Remove plasma without disturbing the buffy coat or cell layer at the bottom of the tube.



5 Cap and centrifuge plasma at 1500 x g for 15 minutes.




6 Use a plastic pipette to transfer plasma to a plastic tube without disturbing the buffy coat or cell layer.



7 Transfer plasma to plastic storage tubes. Ideally PPP platelet count should not exceed 10,000/uL.



8 Label tubes with patient information and specimen type (i.e. citrate plasma).



9 FREEZE specimens. Do not use a self-defrosting freezer.



Watch our brief step-by-step video on proper technique for specimen collection at [QuestDiagnostics.com/specimencollection](http://QuestDiagnostics.com/specimencollection).

## Pediatric reference ranges #1

| Test                            | Day 1             | Day 5             | 1 mo. - 1 yr<br>Mean (boundary) | 1 - 5 yr<br>Mean (boundary) | 6 - 10 yr<br>Mean (boundary) | 11 - 16 yr<br>Mean (boundary) | Adult<br>Mean (boundary)      |
|---------------------------------|-------------------|-------------------|---------------------------------|-----------------------------|------------------------------|-------------------------------|-------------------------------|
| PT (s)                          | 13 (11.6-14.43)   | 12.4 (10.5-13.86) | 12.3 (10.7-13.9)                | 11 (10.6-11.4)              | 11.1 (10.1-12.1)             | 11.2 (10.2 – 12.0)            | 12 (11.0-14.0)                |
| INR                             | 1 (0.53-1.62)     | 0.91 (0.53-1.48)  | 0.88 (0.61-1.17)                | 1.0 (0.96-1.04)             | 1.01 (0.91-1.11)             | 1.02 (0.93-1.10)              | 1.10 (1.0-1.3)                |
| aPTT (s)                        | 42.9 (31.3-54.5)  | 42.6 (25.4-59.8)  | 35.5 (28.1-42.9)                | 30 (0.24-0.36)              | 31 (26-36)                   | 32 (26-37)                    | 33 (27-40)                    |
| Fibrinogen (g/L)                | 2.83 (2.25-3.41)  | 3.12 (2.37-3.87)  | 2.51 (1.5-3.87)                 | 2.76 (1.70-4.05)            | 2.79 (1.57-40)               | 3.0 (1.54-4.48)               | 2.78 (1.56-4.0)               |
| Factor II (U/mL)                | 0.48 (0.37-0.59)  | 0.63 (0.48-0.78)  | 0.88 (0.60-1.16)                | 0.94 (0.71-1.16)            | 0.88 (0.67-1.07)             | 0.83 (0.61-1.04)              | 1.08 (0.70-1.46)              |
| Factor V (U/mL)                 | 0.72 (0.54-0.90)  | 0.95 (0.70-1.20)  | 0.91 (0.55-1.27)                | 1.03 (0.79-1.27)            | 0.90 (0.63-1.16)             | 0.77 (0.55-0.99)              | 1.06 (0.62-1.50)              |
| Factor VII (U/mL)               | 0.66 (0.47- 0.85) | 0.89 (0.62-1.16)  | 0.87 (0.47-1.27)                | 0.82 (0.55-1.16)            | 0.85 (0.52-1.20)             | 0.83 (0.58-1.15)              | 1.05 (0.67-1.43)              |
| Factor VIII (U/mL)              | 1.00 (0.61-1.39)  | 0.88 (0.55-1.21)  | 0.73 (0.50-1.09)                | 0.90 (0.59-1.42)            | 0.95 (0.58-1.32)             | 0.92 (0.53-1.31)              | 0.99 (0.50-1.49)              |
| vWF:Ag (U/mL) <sup>b</sup>      | ND                | ND                | 0.82 (0.53-1.53)                | 0.86 (0.52-1.40)            | 0.91 (0.58-1.45)             | 0.93 (0.57-1.47)              | 1.11 (0.65-1.82) <sup>b</sup> |
| vWF:Rco (U/mL) <sup>b</sup>     | ND                | ND                | 0.73 (0.51-1.50)                | 0.74 (0.51-1.28)            | 0.77 (0.46-1.38)             | 0.85 (0.51-1.47)              | 0.93 (0.56-1.50) <sup>b</sup> |
| Factor IX (U/mL)                | 0.53 (0.34-0.72)  | 0.53 (0.34-0.72)  | 0.86 (0.36-1.36)                | 0.73 (0.47-1.04)            | 0.75 (0.63-00.89)            | 0.82 (0.59-1.22)              | 1.09 (0.55-1.63)              |
| Factor X (U/mL)                 | 0.40 (0.26-0.54)  | 0.49 (0.34-0.64)  | 0.78 (0.38-1.18)                | 0.88 (0.58-1.16)            | 0.75 (0.55-1.01)             | 0.79 (0.50-0.97)              | 1.06 (0.70-1.52)              |
| Factor XI (U/mL)                | 0.38 (0.24-0.52)  | 0.55 (0.39-0.71)  | 0.86 (0.49-1.34)                | 0.97 (0.56-1.50)            | 0.86 (0.52-1.20)             | 0.74 (0.50-0.97)              | 0.97 (0.67-1.27)              |
| Factor XII (U/mL)               | 0.53 (0.33-0.73)  | 0.47 (0.29-0.65)  | 0.77 (0.39-1.15)                | 0.93 (0.64-1.29)            | 0.92 (0.60-1.40)             | 0.81 (0.34-1.37)              | 1.08 (0.52-1.64)              |
| Factor XIII (U/mL) <sup>a</sup> | 1.79 (0.67-2.82)  | 2.15 (0.26-3.16)  | 2.57 (0.99-4.78)                | 2.09 (0.67-3.73)            | 2.42 (0.31-7.85)             | 2.60 (0.12-6.01)              | 2.67 (0.47-7.94)              |

ND (no data from Appel IM 2012)<sup>1</sup>

<sup>a</sup>Attard C et al, 2012; results shown for day 5 are actually day 3 results<sup>2</sup>

<sup>b</sup>Appel IM et al, 2012; results shown for 1 mo-1 yr are actually 7-12 mo results, 11-16 yr are actually 11-18 yr results, and adult are actually >19 yr results<sup>1</sup>

Note: This table is to be used to gauge relative differences between age-specific intervals as methodology and reagents used in these studies may be different than what is currently used by Quest Diagnostics.

Quest Diagnostics has not established normal reference intervals for all factor levels for children <18 years old. The table above gives age-adjusted reference intervals for pediatric levels for comparison purposes based on published studies. Quest Diagnostics' established pediatric reference intervals may differ based on test methodology differences and population studied. The values are expressed by the upper and lower boundary encompassing approximately 95% of the population.

Factor levels are converted from the original tables, which express values as units/mL. Original tables provide values for infants at 1 day, 5 days, and 1 mo - 1 yr of age as well as for children 1-5 years, 6-10 years, and 11-16 years, as described by Monagle 2006.<sup>3</sup> The published tables have been converted to the reference intervals shown.

### Reference:

1. Appel IM et al. Age dependency of coagulation parameters during childhood and puberty. *J Thromb Haemost.* 2012;10(11):2254-63. doi:10.1111/j.1538-7836.2012.04905.x
2. Attard C et al. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. [published correction appears in *J Thromb Haemost* 2019;17(11):1995. doi:10.1111/jth.14655]. *J Thromb Haemost* 2013;11(10):1850-1854. doi:10.1111/jth.12372.
3. Monagle P et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. *Thromb Haemost.* 2006;95(2):362-372. doi:10.1160/TH05-01-0047.

## Pediatric reference ranges #2

| Test                | Day 1            | Day 5            | 1 mo. - 1 yr<br>Mean (boundary) | 1 - 5 yr<br>Mean (boundary) | 6 - 10 yr<br>Mean (boundary) | 11 - 16 yr<br>Mean (boundary) | Adult<br>Mean (boundary) |
|---------------------|------------------|------------------|---------------------------------|-----------------------------|------------------------------|-------------------------------|--------------------------|
| ATIII (%)           | 63 (51-75)       | 67 (54-80)       | 104 (84-124)                    | 111 (82-139)                | 111 (90-131)                 | 105 (77-132)                  | 100 (74-126)             |
| PS Free (%)*        | 25 (18-29)       | 34 (22-51)       | 64 (33-95)                      | 68 (41-146)                 | 68 (44-104)                  | 65 (41-103)                   | 86 (35-142)              |
| PS Total (%)*       | 10 (6-17)        | 12 (4-24)        | 27 (5-47)                       | 33 (15-52)                  | 36 (18-55)                   | 39 (20-57)                    | 50 (18-105)              |
| PC Activity (%)     | 35 (26-44)       | 42 (31-53)       | 59 (37-81)                      | 66 (40-92)                  | 69 (45-93)                   | 83 (55-111)                   | 96 (64-128)              |
| a2M (U/mL)          | ND               | ND               | ND                              | 1.69 (1.14-2.23)            | 1.69 (1.28-2.09)             | 1.56 (0.98-2.12)              | 0.86 (0.52-1.20)         |
| C1-Inh (U/mL)       | ND               | ND               | ND                              | 1.35 (0.85-1.83)            | 1.14 (0.88-1.54)             | 1.03 (0.68-1.50)              | 1.0 (0.71-1.31)          |
| PAI (U/mL)          | ND               | ND               | ND                              | 5.42 (1.0-10.0)             | 6.79 (2.0-12.0)              | 6.07 (2.0-10.0)               | 3.60 (0-11.0)            |
| Plasminogen* (U/mL) | 0.38 (0.18-0.84) | 0.69 (0.37-1.29) | 1.01 (0.68-1.77)                | 1.87 (0.84-3.33)            | 1.82 (0.87-3.13)             | 1.18(0.50-2.78)               | 2.62 (0.57-8.14)         |

ATIII, Antithrombin III (also known as Antithrombin); PS, Protein S; PC, Protein C; a2M, a2 macroglobulin; C1-Inh, C1 esterase inhibitor; HCII, heparin cofactor II; PAI-1, plasminogen activator inhibitor-1. ND, no data from Andrew.<sup>1</sup>

\*Results shown for day 5 are actually day 3 results.<sup>2</sup>

Note: This table is to be used to gauge relative differences between age-specific intervals as methodology and reagents used in these studies may be different than what is currently used by Quest Diagnostics.

Quest Diagnostics has not established normal reference intervals for all factor levels for children <18 years old. The table above gives age-adjusted reference intervals for pediatric levels for comparison purposes based on published studies. Quest Diagnostics' established pediatric reference intervals may differ based on test methodology differences and population studied. The values are expressed by the upper and lower boundary encompassing approximately 95% of the population.

Factor levels are converted from the original tables, which express values as units/mL. Original tables provide values for infants at 1 day, 5 days, and 1 mo - 1 yr of age as well as for children 1-5 years, 6-10 years, and 11-16 years, as described by Monagle 2006.<sup>3</sup> The published tables have been converted to the reference intervals shown.

### Reference:

- Andrew M et al. Maturation of the Hemostatic System During Childhood. *Blood*. 1992;80(8):1998-2005. doi:10.1182/blood.V80.8.1998.1998.
- Attard C et al. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. [published correction appears in *J Thromb Haemost* 2019;17(11):1995. doi:10.1111/jth.14655]. *J Thromb Haemost* 2013;11(10):1850-1854. doi:10.1111/jth.12372.
- Monagle P et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. *Thromb Haemost*. 2006;95(2):362-372. doi:10.1160/TH05-01-0047.



Watch our brief, step-by-step video on proper technique for specimen collection ▶



Questions? See our testing FAQs or visit [QuestDiagnostics.com/BT](https://www.questdiagnostics.com/BT).  
To see our comprehensive test menu, go to [TestDirectory.QuestDiagnostics.com](https://www.questdiagnostics.com/TestDirectory).



For information relating to bleeding and thrombosis test selection, use, and interpretation of results, call **1.866.MY.QUEST (1.866.697.8378)** or contact a Quest Diagnostics representative.



Additionally, you may contact our Quest Diagnostics directly:  
Quest Diagnostics – Chantilly, VA **1.800.336.3718**  
Quest Diagnostics – San Juan Capistrano, CA **1.800.642.4657**



[QuestDiagnostics.com](https://www.questdiagnostics.com)

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third party marks—® and ™—are the property of their respective owners. © 2020-2024 Quest Diagnostics Incorporated. All rights reserved. SB5219 8/2024